The Moore's Law publication offers a benchmark, sure, but it's not the decisive driver for genome sequencing costs.
These trends are conditional, not automatic; you need actual funding commitments to see real-world application.
Without continuous investment in research and healthcare infrastructure, like setting aside a canton's budget for new genetic diagnostics, the cost per genome means little to ordinary people.
We should always commit to looking at practical investment over abstract predictions.